Asahi Kasei Bioprocess to showcase at Achema 2022
Asahi Kasei Bioprocess, subsidiary of diversified Japanese technology company Asahi Kasei, will be featuring their MOTIV Buffer Management Technology at Achema 2022 in Frankfurt this August.
Using built-in automation software, MOTIV keeps pharmaceutical production moving efficiently and precisely, so that medicine can be produced in larger quantities, be made more available globally and can get to patients sooner and safer.
Buffers are used for the vast majority of processes in pharmaceutical development, which has traditionally required storage in extremely large tank farms to be utilised as necessary. MOTIV can blend buffers from concentrates in small, single-use bags and is controlled with sensors to maintain and assure precision. It is also able to blend buffers to exact specifications as needed during a downstream development process and can handle a wide variety of buffer formulations. In addition, it is automated by the integrated OCELOT System Control software, a technology that integrates and/or interfaces with plant-wide control systems in a universally compatible format, allowing for far-reaching data collection and analysis. OCELOT makes the whole process repeatable and also helps to reduce waste created in the development process, so it is a more sustainable means of pharmaceutical manufacturing.
“We have been working to ‘standardise’ system designs as much as we can, to make them more readily available with shorter lead times; but are also very capable at building custom systems to meet the specific needs of customers,” says Chris Rombach, vice president of sales and marketing at Asahi Kasei Bioprocess America. “One of our strengths is not only having an innovative product, but also an extensive family of MOTIV systems to choose from. Buffer is the lifeblood of pharma manufacturing and with the R&D opportunities of being a part of the Asahi Kasei Group we have been able to develop MOTIV to be the most reliable and efficient IBF technology in the market today.”